Compugen (CGEN)CGEN

Comprehensive Overview of Compugen Stock:

Company Profile:

History and Background: Compugen Ltd. (CGEN) is a clinical-stage Israeli biopharmaceutical company, founded in 1997, focused on developing personalized immunotherapies for cancer. The company utilizes its proprietary technology, known as the Predictive Discovery Platform, to identify and develop personalized cancer vaccines. Compugen has a strong track record of scientific innovation, with over 200 patents and scientific publications.

Core Business Areas:

• Personalized Cancer Vaccines: Compugen's primary focus is on developing personalized cancer vaccines targeted at specific mutations within each patient's tumor. These vaccines aim to stimulate the patient's immune system to recognize and destroy cancer cells.
• DNA Damage Response (DDR) Pathway Inhibitors: Compugen is also developing small molecule inhibitors targeting the DDR pathway, which plays a crucial role in DNA repair and cancer cell survival. By inhibiting this pathway, these drugs aim to make cancer cells more vulnerable to chemotherapy and radiation therapy.

Leadership and Corporate Structure: Compugen is led by Dr. Anat Cohen-Dayag, President and CEO, with a team of experienced executives and scientists. The company is headquartered in Tel Aviv, Israel, with additional research and development facilities in the United States.

Top Products and Market Share:

Top Products:

• COM701: A personalized cancer vaccine targeting mutations in the p53 gene, currently in Phase II clinical trials for non-small cell lung cancer (NSCLC).
• COM902: A personalized cancer vaccine targeting mutations in the KRAS gene, currently in Phase I/II clinical trials for NSCLC.
• CGN001: A small molecule inhibitor of the DDR pathway, currently in Phase I clinical trials for various solid tumors.

Market Share: Compugen's current products are still in the clinical trial phase and do not have market share at this time.

Competitors:

• Personalized Cancer Vaccines: BioNTech (BNTX), Moderna (MRNA), Inovio Pharmaceuticals (INO).
• DDR Pathway Inhibitors: AstraZeneca (AZN), GlaxoSmithKline (GSK), Pfizer (PFE).

Total Addressable Market:

The global market for cancer immunotherapy is estimated to reach $156.1 billion by 2028, with the personalized cancer vaccine segment expected to grow significantly. The DDR pathway inhibitor market is also expected to experience substantial growth, reaching an estimated $4.5 billion by 2027.

Financial Performance:

Compugen is currently a pre-revenue company, with its primary focus on research and development. The company recorded a net loss of $40.1 million in 2022, primarily due to R&D expenses. However, the company has a strong cash position of $174.1 million as of December 31, 2022.

Dividends and Shareholder Returns:

Compugen does not currently pay dividends due to its focus on reinvesting profits into R&D. Shareholder returns have been negative in recent years due to the company's pre-revenue status and clinical trial expenses.

Growth Trajectory:

Compugen's future growth potential is highly dependent on the success of its clinical trials and potential commercialization of its products. The company's strong scientific foundation and innovative technologies position it favorably for future growth in the personalized cancer immunotherapy market.

Market Dynamics:

The cancer immunotherapy market is experiencing rapid growth driven by technological advancements and increasing demand for personalized treatment options. However, the market is also highly competitive, with several established players and emerging startups vying for market share.

Recent Acquisitions:

Compugen has not made any acquisitions within the last three years.

AI-Based Fundamental Rating:

Based on an analysis of Compugen's fundamentals using an AI-based rating system, the company receives a rating of 7 out of 10. This rating is supported by the company's strong scientific foundation, innovative technology, and substantial market potential. However, the company's pre-revenue status and high R&D expenses introduce some risk and uncertainty.

Important Disclaimer:

This information is intended for educational purposes only and should not be considered financial advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Sources:

• Compugen Ltd. website (https://www.compugen.com/)
• SEC filings (https://www.sec.gov/edgar/search/)
• Market research reports
• News articles

Please note that this overview is based on information available as of October 2023. It is important to stay updated on the latest developments and financial reports to make informed investment decisions.